HMSC-mediated concurrent delivery of endostatin and carboxylesterase to mouse xenografts suppresses glioma initiation and recurrence

Molecular Therapy

Volumn 19, Issue 6, 2011, Pages 1161-1169

  Yin, Jinlong ^a   Kim, Jun Kyum ^b   Moon, Jai Hee ^b   Beck, Samuel ^a   Piao, Dachuan ^a   Jin, Xun ^b   Kim, Sung Hak ^b   Lim, Young Chang ^c   Nam, Do Hyun ^d   You, Seungkwon ^b   Kim, Hyunggee ^b   Choi, Yun Jaie ^a  

^a Seoul National University   (South Korea)

^b Korea University   (South Korea)

^c Konkuk University School of Medicine   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLESTERASE; ENDOSTATIN; IRINOTECAN; NESTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RECURRENCE; CANCER STEM CELL; CELL COUNT; CELL DEATH; CELL LINE; CELL POPULATION; CONTROLLED STUDY; DISEASE MODEL; GENETIC ENGINEERING; GENETIC TRANSDUCTION; GLIOBLASTOMA; GLIOMA STEM CELL; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NEUROBLASTOMA; NEUROSURGERY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; TREATMENT OUTCOME; TUMOR XENOGRAFT;

EID: 79957897226     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.28     Document Type: Article

References (41)

1. Wen, PY and Kesari, S (2008). Malignant gliomas in adults. N Engl J Med 359: 492-507.
2. Vescovi, AL, Galli, R and Reynolds, BA (2006). Brain tumour stem cells. Nat Rev Cancer 6: 425-436.
3. Singh, SK, Clarke, ID, Terasaki, M, Bonn, VE, Hawkins, C, Squire, J et al. (2003). Identifcation of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828. (Pubitemid 37187480)
4. Murat, A, Migliavacca, E, Gorlia, T, Lambiv, WL, Shay, T, Hamou, MF et al. (2008). Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol 26: 3015-3024.
5. Bleau, AM, Hambardzumyan, D, Ozawa, T, Fomchenko, EI, Huse, JT, Brennan, CW et al. (2009). PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4: 226-235.
6. Bao, S, Wu, Q, McLendon, RE, Hao, Y, Shi, Q, Hjelmeland, AB et al. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760. (Pubitemid 44949604)
7. Al-Hajj, M, Becker, MW, Wicha, M, Weissman, I and Clarke, MF (2004). Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 14: 43-47. (Pubitemid 38167476)
8. Calabrese, C, Poppleton, H, Kocak, M, Hogg, TL, Fuller, C, Hamner, B et al. (2007). A perivascular niche for brain tumor stem cells. Cancer Cell 11: 69-82. (Pubitemid 46054518)
9. Moustakas, A and Kreisl, TN (2010). New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab. Onco Targets Ther 3: 27-38.
10. Friedman, HS, Prados, MD, Wen, PY, Mikkelsen, T, Schiff, D, Abrey, LE et al. (2009). Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27: 4733-4740.
11. Jiang, Y, Jahagirdar, BN, Reinhardt, RL, Schwartz, RE, Keene, CD, Ortiz-Gonzalez, XR et al. (2002). Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418: 41-49. (Pubitemid 34742565)
12. Mareschi, K, Ferrero, I, Rustichelli, D, Aschero, S, Gammaitoni, L, Aglietta, M et al. (2006). Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow. J Cell Biochem 97: 744-754.
13. Aboody, KS, Najbauer, J and Danks, MK (2008). Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther 15: 739-752. (Pubitemid 351627357)
14. Colter, DC, Class, R, DiGirolamo, CM and Prockop, DJ (2000). Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow. Proc Natl Acad Sci USA 97: 3213-3218. (Pubitemid 30183281)
15. Conget, PA and Minguell, JJ (2000). Adenoviral-mediated gene transfer into ex vivo expanded human bone marrow mesenchymal progenitor cells. Exp Hematol 28: 382-390. (Pubitemid 30214150)
16. Nakamizo, A, Marini, F, Amano, T, Khan, A, Studeny, M, Gumin, J et al. (2005). Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65: 3307-3318. (Pubitemid 40524615)
17. Hamada, H, Kobune, M, Nakamura, K, Kawano, Y, Kato, K, Honmou, O et al. (2005). Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci 96: 149-156. (Pubitemid 40575915)
18. Sasportas, LS, Kasmieh, R, Wakimoto, H, Hingtgen, S, van de Water, JA, Mohapatra, G et al. (2009). Assessment of therapeutic effcacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA 106: 4822-4827.
19. O'Reilly, MS, Boehm, T, Shing, Y, Fukai, N, Vasios, G, Lane, WS et al. (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285. (Pubitemid 28015876)
20. Dhanabal, M, Ramchandran, R, Volk, R, Stillman, IE, Lombardo, M, Iruela-Arispe, ML et al. (1999). Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res 59: 189-197. (Pubitemid 29062977)
21. Satoh, T, Hosokawa, M, Atsumi, R, Suzuki, W, Hakusui, H and Nagai, E (1994). Metabolic activation of CPT-11, 7-ethyl-10-[4-(1-piperidino)-1- piperidino] carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull 17: 662-664. (Pubitemid 24186112)
22. Gupta, E, Mick, R, Ramirez, J, Wang, X, Lestingi, TM, Vokes, EE et al. (1997). Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 15: 1502-1510. (Pubitemid 27167386)
23. Negoro, S, Fukuoka, M, Masuda, N, Takada, M, Kusunoki, Y, Matsui, K et al. (1991). Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83: 1164-1168.
24. Oosterhoff, D, Witlox, MA, van Beusechem, VW, Haisma, HJ, Schaap, GR, Bras, J et al. (2003). Gene-directed enzyme prodrug therapy for osteosarcoma: sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2. Mol Cancer Ther 2: 765-771.
25. Yoon, BS, Moon, JH, Jun, EK, Kim, J, Maeng, I, Kim, JS et al. (2010). Secretory profles and wound healing effects of human amniotic fuid-derived mesenchymal stem cells. Stem Cells Dev 19: 887-902.
26. Joki, T, Machluf, M, Atala, A, Zhu, J, Seyfried, NT, Dunn, IF et al. (2001). Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotechnol 19: 35-39. (Pubitemid 32051953)
27. Sugawa, N, Ekstrand, AJ, James, CD and Collins, VP (1990). Identical splicing of aberrant epidermal growth factor receptor transcripts from amplifed rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87: 8602-8606.
28. Reyes, M and Verfaillie, CM (2001). Characterization of multipotent adult progenitor cells, a subpopulation of mesenchymal stem cells. Ann N Y Acad Sci 938: 231-233; discussion 233.
29. Xu, W, Zhang, X, Qian, H, Zhu, W, Sun, X, Hu, J et al. (2004). Mesenchymal stem cells from adult human bone marrow differentiate into a cardiomyocyte phenotype in vitro. Exp Biol Med (Maywood) 229: 623-631. (Pubitemid 38878907)
30. Inda, MM, Bonavia, R, Mukasa, A, Narita, Y, Sah, DW, Vandenberg, S et al. (2010). Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 24: 1731-1745.
31. Williams, J, Lansdown, R, Sweitzer, R, Romanowski, M, LaBell, R, Ramaswami, R et al. (2003). Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors. J Control Release 91: 167-172. (Pubitemid 37288887)
32. Son, MJ, Woolard, K, Nam, DH, Lee, J and Fine, HA (2009). SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 4: 440-452.
33. Sirko, S, von Holst, A, Wizenmann, A, Götz, M and Faissner, A (2007). Chondroitin sulfate glycosaminoglycans control proliferation, radial glia cell differentiation and neurogenesis in neural stem/progenitor cells. Development 134: 2727-2738. (Pubitemid 47307229)
34. Ramírez-Castillejo, C, Sánchez-Sánchez, F, Andreu-Agulló, C, Ferrón, SR, Aroca-Aguilar, JD, Sánchez, P et al. (2006). Pigment epithelium-derived factor is a niche signal for neural stem cell renewal. Nat Neurosci 9: 331-339. (Pubitemid 43290962)
35. Bar, EE, Chaudhry, A, Lin, A, Fan, X, Schreck, K, Matsui, W et al. (2007). Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 25: 2524-2533. (Pubitemid 47582744)
36. Liu, F, Tan, G, Li, J, Dong, X, Krissansen, GW and Sun, X (2007). Gene transfer of endostatin enhances the effcacy of doxorubicin to suppress human hepatocellular carcinomas in mice. Cancer Sci 98: 1381-1387. (Pubitemid 47241760)
37. Minniti, G, Muni, R, Lanzetta, G, Marchetti, P and Enrici, RM (2009). Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents. Anticancer Res 29: 5171-5184.
38. Beug, H (2009). Breast cancer stem cells: eradication by differentiation therapy? Cell 138: 623-625.
39. Massard, C, Deutsch, E and Soria, JC (2006). Tumour stem cell-targeted treatment: elimination or differentiation. Ann Oncol 17: 1620-1624. (Pubitemid 44680880)
40. Yoon, SS, Eto, H, Lin, CM, Nakamura, H, Pawlik, TM, Song, SU et al. (1999). Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res 59: 6251-6256. (Pubitemid 30035650)
41. Leon, SP, Folkerth, RD and Black, PM (1996). Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 77: 362-372 (Pubitemid 26023356)